DiognosisReference facts
Back to Diognosis Data views Class guides

Diognosis V1 Reference Facts

Static medication-review summaries generated from the same local Diognosis runtime used by the app. This page is designed for humans, search crawlers, LLM retrieval, and audit checks without loading the full app bundle.

85 facts 79 source-linked 85 provenance-classified Educational only; no runtime uploads

Boundary

Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.

JSON facts
Full metadata and facts array
JSONL facts
One fact per line for RAG pipelines
llms.txt
Curated retrieval entry points
critical Statins and Lipid Medicines interaction_example

Simvastatin + clarithromycin

Simvastatin + Clarithromycin

Review question

Simvastatin exposure may rise with Clarithromycin

Can you check whether this combination could raise muscle pain or muscle injury risk?

Mechanism summary

Simvastatin exposure may rise with Clarithromycin

Clarithromycin may increase Simvastatin exposure, raising Simvastatin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 8 sources · mechanistic high · authority-linked

  • ev_simvastatin_label_cyp3a4Simvastatin (Zocor) Prescribing Information — Contraindicated and dose-limited interactions
  • PMID 12036392Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors
  • PMID 26367500Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid
  • PMID 35152405CPIC Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms
critical Statins and Lipid Medicines interaction_example

Simvastatin + itraconazole

Simvastatin + Itraconazole

Review question

Simvastatin exposure may rise with Itraconazole

Can you check whether this combination could raise muscle pain or muscle injury risk?

Mechanism summary

Simvastatin exposure may rise with Itraconazole

Itraconazole may increase Simvastatin exposure, raising Simvastatin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 8 sources · mechanistic high · authority-linked

  • ev_simvastatin_label_cyp3a4Simvastatin (Zocor) Prescribing Information — Contraindicated and dose-limited interactions
  • PMID 12036392Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors
  • PMID 26367500Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid
  • PMID 35152405CPIC Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms
critical Statins and Lipid Medicines interaction_example

Simvastatin + gemfibrozil

Simvastatin + Gemfibrozil

Review question

Simvastatin exposure may rise with Gemfibrozil

Can you check whether this combination could raise muscle pain or muscle injury risk?

Mechanism summary

Simvastatin exposure may rise with Gemfibrozil

Gemfibrozil may increase Simvastatin exposure, raising Simvastatin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 4 sources · mechanistic high · authority-linked

  • PMID 15116058The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
  • ev_simvastatin_label_cyp3a4Simvastatin (Zocor) Prescribing Information — Contraindicated and dose-limited interactions
moderate Statins and Lipid Medicines interaction_example

Atorvastatin + clarithromycin

Atorvastatin + Clarithromycin

Review question

Atorvastatin exposure may rise with Clarithromycin

Can you check whether this combination could raise muscle pain or muscle injury risk?

Mechanism summary

Atorvastatin exposure may rise with Clarithromycin

Clarithromycin may increase Atorvastatin exposure, raising Atorvastatin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

guideline · 5 sources · mechanistic high · authority-linked

  • PMID 35152405CPIC Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms
severe Statins and Lipid Medicines interaction_example

Rosuvastatin + gemfibrozil

Rosuvastatin + Gemfibrozil

Review question

Rosuvastatin exposure may rise with Gemfibrozil

Can you check whether this combination could raise muscle pain or muscle injury risk?

Mechanism summary

Rosuvastatin exposure may rise with Gemfibrozil

Gemfibrozil may increase Rosuvastatin exposure, raising Rosuvastatin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 2 sources · mechanistic high · authority-linked

  • PMID 15116058The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
  • ev_rosuvastatin_labelRosuvastatin (Crestor) Prescribing Information — OATP1B1/BCRP inhibitor interactions
critical Statins and Lipid Medicines interaction_example

Nirmatrelvir/ritonavir + simvastatin

Nirmatrelvir/Ritonavir + Simvastatin

Review question

Simvastatin exposure may rise with Nirmatrelvir/Ritonavir

Can you check whether this combination could raise muscle pain or muscle injury risk?

Mechanism summary

Simvastatin exposure may rise with Nirmatrelvir/Ritonavir

Nirmatrelvir/Ritonavir may increase Simvastatin exposure, raising Simvastatin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 8 sources · mechanistic high · authority-linked

  • ev_paxlovid_cyp3a_labelPaxlovid prescribing information - CYP3A inhibition and strong inducer contraindications
  • PMID 26367500Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid
  • ev_simvastatin_label_cyp3a4Simvastatin (Zocor) Prescribing Information — Contraindicated and dose-limited interactions
  • PMID 35152405CPIC Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms
severe Statins and Lipid Medicines interaction_example

Darolutamide + rosuvastatin

Darolutamide + Rosuvastatin

Review question

Darolutamide exposure may rise with Rosuvastatin

Can you check whether this combination could raise muscle pain or muscle injury risk?

Mechanism summary

Darolutamide exposure may rise with Rosuvastatin

Rosuvastatin may increase Darolutamide exposure, raising Darolutamide toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 2 sources · mechanistic high · authority-linked

moderate Statins and Lipid Medicines interaction_example

Leflunomide + rosuvastatin

Leflunomide + Rosuvastatin

Review question

Rosuvastatin exposure may rise with Leflunomide

Can you check whether this combination could raise muscle pain or muscle injury risk?

Mechanism summary

Rosuvastatin exposure may rise with Leflunomide

Leflunomide may increase Rosuvastatin exposure, raising Rosuvastatin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

critical Blood Pressure and Heart Failure interaction_example

Potassium chloride + spironolactone

Potassium Chloride + Spironolactone

Review question

High potassium risk may increase

Can you check whether this list could raise potassium or kidney-related monitoring concerns?

Mechanism summary

High potassium risk may increase

Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

fda label · 2 sources · mechanistic high · authority-linked

  • ev_potassium_hyperkalemia_labelPotassium chloride prescribing information - hyperkalemia risk with potassium-retaining medicines
  • PMID 21911446Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study
moderate Blood Pressure and Heart Failure interaction_example

Potassium chloride + lisinopril

Potassium Chloride + Lisinopril

Review question

High potassium risk may increase

Can you check whether this list could raise potassium or kidney-related monitoring concerns?

Mechanism summary

High potassium risk may increase

Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

moderate Blood Pressure and Heart Failure interaction_example

Spironolactone + TMP-SMX

Spironolactone + Trimethoprim/Sulfamethoxazole

Review question

High potassium risk may increase

Can you check whether this list could raise potassium or kidney-related monitoring concerns?

Mechanism summary

High potassium risk may increase

Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

observational · 1 source · mechanistic moderate · primary-literature linked

  • PMID 21911446Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study
critical Blood Pressure and Heart Failure interaction_example

Sacubitril/valsartan + lisinopril

Sacubitril/Valsartan + Lisinopril

Review question

High potassium risk may increase

Can you check whether this list could raise potassium or kidney-related monitoring concerns?

Mechanism summary

High potassium risk may increase

Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

critical Blood Pressure and Heart Failure interaction_example

Nitroglycerin + sildenafil

Nitroglycerin + Sildenafil

Review question

Low blood pressure risk may increase

Can you check whether this combination could cause low blood pressure, dizziness, or fainting?

Mechanism summary

Low blood pressure risk may increase

Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

moderate Blood Pressure and Heart Failure interaction_example

Sildenafil + tamsulosin

Sildenafil + Tamsulosin

Review question

Low blood pressure risk may increase

Can you check whether this combination could cause low blood pressure, dizziness, or fainting?

Mechanism summary

Low blood pressure risk may increase

Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

modeled review prompt · no linked sources · mechanistic moderate · modeled review prompt

No direct public source URL is available in the top exported evidence refs. See evidenceRefs in the JSON export.

severe Blood Pressure and Heart Failure interaction_example

Ibuprofen + lisinopril

Ibuprofen + Lisinopril

Review question

High potassium risk may increase

Can you check whether this list could raise potassium or kidney-related monitoring concerns?

Mechanism summary

High potassium risk may increase

Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

modeled review prompt · no linked sources · mechanistic moderate · modeled review prompt

No direct public source URL is available in the top exported evidence refs. See evidenceRefs in the JSON export.

moderate Blood Pressure and Heart Failure interaction_example

Terbinafine + metoprolol

Terbinafine + Metoprolol

Review question

Metoprolol exposure may rise with Terbinafine

Can you check whether my gene result could raise Metoprolol side effects, pulse, blood pressure, or monitoring needs?

Mechanism summary

Metoprolol exposure may rise with Terbinafine

Terbinafine may increase Metoprolol exposure, raising Metoprolol toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

guideline · 4 sources · mechanistic high · authority-linked

severe Anticoagulants and Antiplatelets interaction_example

Warfarin + fluconazole + ibuprofen

Warfarin + Fluconazole + Ibuprofen

Review question

Bleeding burden may rise

Can you check whether Warfarin + Ibuprofen needs closer bleeding or clotting monitoring?

Mechanism summary

Bleeding burden may rise

Bleeding burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

guideline · 6 sources · mechanistic high · authority-linked

  • PMID 32189324CPIC Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs
  • PMID 11176762Risk of upper gastrointestinal bleeding with warfarin and NSAIDs: a case-control study
  • PMID 8801057Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies
severe Anticoagulants and Antiplatelets interaction_example

Warfarin + TMP-SMX

Warfarin + Trimethoprim/Sulfamethoxazole

Review question

Bleeding burden may rise

Can you check whether Warfarin + Trimethoprim/Sulfamethoxazole needs closer bleeding or clotting monitoring?

Mechanism summary

Bleeding burden may rise

Bleeding burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

fda label · 5 sources · mechanistic high · authority-linked

  • ev_tmp_smx_labelSulfamethoxazole/trimethoprim prescribing information - warfarin, OCT2/CYP2C8, and folate-toxicity context
  • PMID 24657899Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans
critical Anticoagulants and Antiplatelets interaction_or_pgx_example

Clopidogrel + omeprazole with CYP2C19 PM

Clopidogrel + Omeprazole; CYP2C19:PM

Review question

Clopidogrel activation to Active thiol metabolite may be reduced with Omeprazole

Can you check whether Clopidogrel may work less well with my current list?

Mechanism summary

Clopidogrel activation to Active thiol metabolite may be reduced with Omeprazole

Increased stent thrombosis and MI risk. FDA warning Additional grouped signal: Clopidogrel exposure may fall with Omeprazole; CYP2C19 behaves as poor function. Related genotype, pathway, and metabolite signals are grouped below.

Evidence status

rct · 7 sources · mechanistic high · authority-linked

  • PMID 35034351Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
  • PMID 32770672CPIC Guideline for CYP2C19 and Proton Pump Inhibitor Dosing
  • PMID 25196410CYP2C19 phenotype effect on clopidogrel active thiol metabolite exposure and platelet inhibition
  • PMID 19106084Cytochrome P-450 polymorphisms and response to clopidogrel
  • PMID 24710841Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers
moderate Anticoagulants and Antiplatelets interaction_example

Apixaban + clarithromycin

Apixaban + Clarithromycin

Review question

Apixaban exposure may rise with Clarithromycin

Can you check whether Apixaban side effects or monitoring needs could increase?

Mechanism summary

Apixaban exposure may rise with Clarithromycin

Clarithromycin may increase Apixaban exposure, raising Apixaban toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 7 sources · mechanistic high · authority-linked

  • PMID 20170205ABCB1/P-glycoprotein pharmacogenetic variants and P-gp substrate exposure
  • ev_doac_rifampin_labelDirect oral anticoagulant Prescribing Information — combined P-gp and strong CYP3A4 inducers
critical Anticoagulants and Antiplatelets interaction_example

Apixaban + rifampin

Apixaban + Rifampin

Review question

Apixaban exposure may rise with Rifampin

Can you check whether Apixaban side effects or monitoring needs could increase?

Mechanism summary

Apixaban exposure may rise with Rifampin

Rifampin may increase Apixaban exposure, raising Apixaban toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 2 sources · mechanistic high · authority-linked

  • PMID 22348256Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin
  • ev_doac_rifampin_labelDirect oral anticoagulant Prescribing Information — combined P-gp and strong CYP3A4 inducers
severe Anticoagulants and Antiplatelets interaction_example

Amiodarone + warfarin

Amiodarone + Warfarin

Review question

Warfarin INR sensitivity may increase

Can you check whether Warfarin side effects or monitoring needs could increase?

Mechanism summary

Warfarin INR sensitivity may increase

Amiodarone may increase Warfarin exposure, raising Warfarin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

guideline · 7 sources · mechanistic high · authority-linked

  • PMID 3401099The incidence, magnitude, and time course of the amiodarone-warfarin interaction
  • PMID 28198005CPIC Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update
moderate Anticoagulants and Antiplatelets interaction_example

Warfarin + acetaminophen

Warfarin + Acetaminophen

Review question

Acetaminophen exposure may rise with Warfarin

Can you check whether Acetaminophen side effects or monitoring needs could increase?

Mechanism summary

Acetaminophen exposure may rise with Warfarin

Warfarin may increase Acetaminophen exposure, raising Acetaminophen toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

modeled review prompt · no linked sources · mechanistic moderate · modeled review prompt

No direct public source URL is available in the top exported evidence refs. See evidenceRefs in the JSON export.

critical Anticoagulants and Antiplatelets interaction_example

Dabigatran + rifampin

Dabigatran + Rifampin

Review question

Rifampin absorption may fall with Dabigatran

Can you check whether Rifampin may not absorb as expected with my current list?

Mechanism summary

Rifampin absorption may fall with Dabigatran

Loss of anticoagulation — avoid/contraindicated Additional grouped signal: Dabigatran transport may change with Rifampin.

Evidence status

fda label · 2 sources · mechanistic high · authority-linked

  • PMID 22348256Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin
  • ev_doac_rifampin_labelDirect oral anticoagulant Prescribing Information — combined P-gp and strong CYP3A4 inducers
moderate Diabetes and Weight-Loss Medicines interaction_example

Metformin + TMP-SMX

Metformin + Trimethoprim/Sulfamethoxazole

Review question

Metformin exposure may rise with Trimethoprim/Sulfamethoxazole

Can you check whether Metformin side effects or monitoring needs could increase?

Mechanism summary

Metformin exposure may rise with Trimethoprim/Sulfamethoxazole

Trimethoprim/Sulfamethoxazole may increase Metformin exposure, raising Metformin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

modeled review prompt · no linked sources · mechanistic moderate · modeled review prompt

No direct public source URL is available in the top exported evidence refs. See evidenceRefs in the JSON export.

moderate Diabetes and Weight-Loss Medicines interaction_example

Dolutegravir + metformin

Dolutegravir + Metformin

Review question

Metformin exposure may rise with Dolutegravir

Can you check whether Metformin side effects or monitoring needs could increase?

Mechanism summary

Metformin exposure may rise with Dolutegravir

Dolutegravir may increase Metformin exposure, raising Metformin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

moderate Diabetes and Weight-Loss Medicines interaction_example

Ranolazine + metformin

Ranolazine + Metformin

Review question

Ranolazine exposure may rise with Metformin

Can you check whether Ranolazine side effects or monitoring needs could increase?

Mechanism summary

Ranolazine exposure may rise with Metformin

Metformin may increase Ranolazine exposure, raising Ranolazine toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

moderate Diabetes and Weight-Loss Medicines interaction_example

Insulin glargine + metoprolol

Insulin Glargine + Metoprolol

Review question

Pharmacodynamic risk may increase

Can you check whether Metoprolol + Insulin Glargine needs closer review?

Mechanism summary

Pharmacodynamic risk may increase

Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

moderate Diabetes and Weight-Loss Medicines interaction_example

Insulin lispro + metoprolol

Insulin Lispro + Metoprolol

Review question

Pharmacodynamic risk may increase

Can you check whether Metoprolol + Insulin Lispro needs closer review?

Mechanism summary

Pharmacodynamic risk may increase

Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

moderate Diabetes and Weight-Loss Medicines interaction_example

Insulin glargine + tirzepatide

Insulin Glargine + Tirzepatide

Review question

Pharmacodynamic risk may increase

Can you check whether Tirzepatide + Insulin Glargine needs closer review?

Mechanism summary

Pharmacodynamic risk may increase

Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

fda label · 2 sources · mechanistic high · authority-linked

monitor Diabetes and Weight-Loss Medicines interaction_example

Tirzepatide + warfarin

Tirzepatide + Warfarin

Review question

Tirzepatide absorption may change with Warfarin

Can you check whether Tirzepatide may not absorb as expected with my current list?

Mechanism summary

Tirzepatide absorption may change with Warfarin

Monitor INR after tirzepatide initiation or dose escalation if warfarin control changes.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

severe Pain, Inflammation, and Migraine interaction_example

Warfarin + ibuprofen

Warfarin + Ibuprofen

Review question

Bleeding burden may rise

Can you check whether Warfarin + Ibuprofen needs closer bleeding or clotting monitoring?

Mechanism summary

Bleeding burden may rise

Bleeding burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

observational · 1 source · mechanistic moderate · primary-literature linked

  • PMID 11176762Risk of upper gastrointestinal bleeding with warfarin and NSAIDs: a case-control study
severe Pain, Inflammation, and Migraine interaction_example

Lithium + naproxen

Lithium + Naproxen

Review question

Lithium exposure may rise with Naproxen

Can you check whether Lithium side effects or monitoring needs could increase?

Mechanism summary

Lithium exposure may rise with Naproxen

Naproxen may increase Lithium exposure, raising Lithium toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

clinical pk · 1 source · mechanistic high · primary-literature linked

  • PMID 2258452Nonsteroidal anti-inflammatory drugs and lithium: a case report and review of the literature
critical Pain, Inflammation, and Migraine interaction_example

Methotrexate + ibuprofen

Methotrexate + Ibuprofen

Review question

Methotrexate exposure may rise with Ibuprofen

Can you check whether this combination could make Methotrexate side effects or lab problems stronger?

Mechanism summary

Methotrexate exposure may rise with Ibuprofen

Ibuprofen may increase Methotrexate exposure, raising Methotrexate toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

clinical pk · 1 source · mechanistic high · primary-literature linked

  • PMID 8882301Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis
moderate Pain, Inflammation, and Migraine interaction_or_pgx_example

Fluoxetine + tramadol with CYP2D6 PM

Fluoxetine + Tramadol; CYP2D6:PM

Review question

Switching and washout timing may need review

Can you check whether this combination raises serotonin-related side effects or switching concerns?

Mechanism summary

Switching and washout timing may need review

Timing and persistence context may remain relevant after stopping or switching. Parent, metabolite, and recovery signals are grouped below.

Evidence status

fda label · 7 sources · mechanistic high · authority-linked

  • ev_fluoxetine_cyp2d6_fdaProzac (fluoxetine) Prescribing Information — Drug Interactions
  • PMID 20184222Stereoselective pharmacokinetics of fluoxetine and norfluoxetine in CYP2D6 poor and extensive metabolizers
  • PMID 37754235Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine
  • PMID 8968657Pharmacokinetic-pharmacodynamic relationships of SSRIs — CYP inhibition rank order
severe Pain, Inflammation, and Migraine interaction_or_pgx_example

Bupropion + codeine with CYP2D6 PM

Bupropion + Codeine; CYP2D6:PM

Review question

Codeine activation to Morphine may be reduced with Bupropion

Can you check whether Codeine may work less well with my current list?

Mechanism summary

Codeine activation to Morphine may be reduced with Bupropion

Bupropion may increase Codeine exposure, raising Codeine toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 5 sources · mechanistic high · authority-linked

  • ev_bupropion_cyp2d6_fdaWellbutrin (bupropion) Prescribing Information — Drug Interactions
  • PMID 8885123Bupropion plasma levels and CYP2D6 phenotype
  • PMID 33387367CPIC guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy
  • PMID 24458010CPIC Guideline for Codeine and CYP2D6
  • PMID 16950362Fatal respiratory depression in neonates — mother CYP2D6 ultrarapid metabolizer on codeine
severe Pain, Inflammation, and Migraine interaction_example

Sertraline + sumatriptan

Sertraline + Sumatriptan

Review question

Serotonin toxicity may rise

Can you check whether this combination raises serotonin-related side effects or switching concerns?

Mechanism summary

Serotonin toxicity may rise

Serotonin toxicity is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

modeled review prompt · no linked sources · mechanistic moderate · modeled review prompt

No direct public source URL is available in the top exported evidence refs. See evidenceRefs in the JSON export.

severe Pain, Inflammation, and Migraine interaction_example

Duloxetine + tizanidine

Duloxetine + Tizanidine

Review question

Tizanidine exposure may rise with Duloxetine

Can you check whether Tizanidine side effects or monitoring needs could increase?

Mechanism summary

Tizanidine exposure may rise with Duloxetine

Duloxetine may increase Tizanidine exposure, raising Tizanidine toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

critical Pain, Inflammation, and Migraine interaction_example

Phenelzine + tramadol

Phenelzine + Tramadol

Review question

Serotonin toxicity may rise

Can you check whether this combination raises serotonin-related side effects or switching concerns?

Mechanism summary

Serotonin toxicity may rise

Serotonin toxicity is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

severe Psychiatry, Neurology, Sleep, and OTC Sedating Medicines interaction_or_pgx_example

Amitriptyline + diazepam + diphenhydramine with CYP2D6 PM

Amitriptyline + Diazepam + Diphenhydramine; CYP2D6:PM

Review question

Amitriptyline activation to 10-Hydroxyamitriptyline may be reduced with Diphenhydramine

Can you check whether Amitriptyline may work less well with my current list?

Mechanism summary

Amitriptyline activation to 10-Hydroxyamitriptyline may be reduced with Diphenhydramine

↑ Anticholinergic burden (confusion, dry mouth, constipation, urinary retention) Additional grouped signal: CYP2D6 behaves as poor function; Amitriptyline exposure may rise with Diphenhydramine. Related genotype, pathway, and metabolite signals are grouped below.

Evidence status

modeled context · 3 sources · mechanistic moderate · modeled context · not severity-bearing

No direct public source URL is available in the top exported evidence refs. See evidenceRefs in the JSON export.

critical Psychiatry, Neurology, Sleep, and OTC Sedating Medicines interaction_example

Lamotrigine + valproic acid

Lamotrigine + Valproic Acid

Review question

Lamotrigine exposure may rise with Valproic Acid

Can you check whether Lamotrigine side effects or monitoring needs could increase?

Mechanism summary

Lamotrigine exposure may rise with Valproic Acid

Valproic Acid may increase Lamotrigine exposure, raising Lamotrigine toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

clinical pk · 1 source · mechanistic high · primary-literature linked

critical Psychiatry, Neurology, Sleep, and OTC Sedating Medicines interaction_example

Phenelzine + sertraline

Phenelzine + Sertraline

Review question

Serotonin toxicity may rise

Can you check whether this combination raises serotonin-related side effects or switching concerns?

Mechanism summary

Serotonin toxicity may rise

Serotonin toxicity is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

critical Psychiatry, Neurology, Sleep, and OTC Sedating Medicines interaction_example

Linezolid + sertraline

Linezolid + Sertraline

Review question

Serotonin toxicity may rise

Can you check whether this combination raises serotonin-related side effects or switching concerns?

Mechanism summary

Serotonin toxicity may rise

Serotonin toxicity is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

  • PMID 21416684FDA Drug Safety Communication: Updated drug labels for linezolid (Zyvox) with new serious drug interaction information (2011)
moderate Psychiatry, Neurology, Sleep, and OTC Sedating Medicines interaction_example

Donepezil + metoprolol

Donepezil + Metoprolol

Review question

Low blood pressure risk may increase

Can you check whether this combination could cause low blood pressure, dizziness, or fainting?

Mechanism summary

Low blood pressure risk may increase

Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

moderate Psychiatry, Neurology, Sleep, and OTC Sedating Medicines interaction_example

Desmopressin + sertraline

Desmopressin + Sertraline

Review question

Sertraline exposure may rise with Desmopressin

Can you check whether this combination raises serotonin-related side effects or switching concerns?

Mechanism summary

Sertraline exposure may rise with Desmopressin

Desmopressin may increase Sertraline exposure, raising Sertraline toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

guideline · 2 sources · mechanistic high · linked source

  • ev_stroke_neurocritical_workflowStroke/thrombolysis/neurocritical medication workflow coverage: fibrinolysis, anticoagulant reversal, hemostasis support, seizure loading, and osmotherapy
critical Antibiotics, Antifungals, and Antivirals interaction_example

Simvastatin + clarithromycin

Simvastatin + Clarithromycin

Review question

Simvastatin exposure may rise with Clarithromycin

Can you check whether this combination could raise muscle pain or muscle injury risk?

Mechanism summary

Simvastatin exposure may rise with Clarithromycin

Clarithromycin may increase Simvastatin exposure, raising Simvastatin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 8 sources · mechanistic high · authority-linked

  • ev_simvastatin_label_cyp3a4Simvastatin (Zocor) Prescribing Information — Contraindicated and dose-limited interactions
  • PMID 12036392Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors
  • PMID 26367500Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid
  • PMID 35152405CPIC Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms
severe Antibiotics, Antifungals, and Antivirals interaction_example

Warfarin + TMP-SMX

Warfarin + Trimethoprim/Sulfamethoxazole

Review question

Bleeding burden may rise

Can you check whether Warfarin + Trimethoprim/Sulfamethoxazole needs closer bleeding or clotting monitoring?

Mechanism summary

Bleeding burden may rise

Bleeding burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

fda label · 5 sources · mechanistic high · authority-linked

  • ev_tmp_smx_labelSulfamethoxazole/trimethoprim prescribing information - warfarin, OCT2/CYP2C8, and folate-toxicity context
  • PMID 24657899Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans
severe Antibiotics, Antifungals, and Antivirals interaction_example

Tacrolimus + voriconazole

Tacrolimus + Voriconazole

Review question

Tacrolimus exposure may rise with Voriconazole

Can you check whether this combination could raise Tacrolimus side effects or monitoring needs?

Mechanism summary

Tacrolimus exposure may rise with Voriconazole

Voriconazole may increase Tacrolimus exposure, raising Tacrolimus toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

guideline · 11 sources · mechanistic high · authority-linked

  • PMID 28224698Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients
  • PMID 25801146Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
  • PMID 18192898Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole
  • PMID 40604035Donor and recipient genetic variants in drug metabolizing enzymes and transporters affect early tacrolimus pharmacokinetics after liver transplantation
  • PMID 34916931Pharmacogenetics Based Dose Prediction Model for Initial Tacrolimus Dosing in Renal Transplant Recipients
critical Antibiotics, Antifungals, and Antivirals interaction_example

Colchicine + clarithromycin

Colchicine + Clarithromycin

Review question

Colchicine exposure may rise with Clarithromycin

Can you check whether Colchicine side effects or monitoring needs could increase?

Mechanism summary

Colchicine exposure may rise with Clarithromycin

Clarithromycin may increase Colchicine exposure, raising Colchicine toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 7 sources · mechanistic high · authority-linked

  • PMID 16007523Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study
  • ev_colchicine_labelColchicine (Colcrys) Prescribing Information — CYP3A4 and P-glycoprotein inhibitors
critical Antibiotics, Antifungals, and Antivirals interaction_example

Tizanidine + ciprofloxacin

Tizanidine + Ciprofloxacin

Review question

CNS depression burden may rise

Can you check whether this list raises confusion, constipation, urination, or fall risk?

Mechanism summary

CNS depression burden may rise

CNS depression burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

fda label · 4 sources · mechanistic high · authority-linked

critical Antibiotics, Antifungals, and Antivirals interaction_example

Dofetilide + TMP-SMX

Dofetilide + Trimethoprim/Sulfamethoxazole

Review question

Trimethoprim/Sulfamethoxazole exposure may rise with Dofetilide

Can you check whether Trimethoprim/Sulfamethoxazole side effects or monitoring needs could increase?

Mechanism summary

Trimethoprim/Sulfamethoxazole exposure may rise with Dofetilide

Dofetilide may increase Trimethoprim/Sulfamethoxazole exposure, raising Trimethoprim/Sulfamethoxazole toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 5 sources · mechanistic high · authority-linked

critical Antibiotics, Antifungals, and Antivirals interaction_example

Nirmatrelvir/ritonavir + simvastatin

Nirmatrelvir/Ritonavir + Simvastatin

Review question

Simvastatin exposure may rise with Nirmatrelvir/Ritonavir

Can you check whether this combination could raise muscle pain or muscle injury risk?

Mechanism summary

Simvastatin exposure may rise with Nirmatrelvir/Ritonavir

Nirmatrelvir/Ritonavir may increase Simvastatin exposure, raising Simvastatin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 8 sources · mechanistic high · authority-linked

  • ev_paxlovid_cyp3a_labelPaxlovid prescribing information - CYP3A inhibition and strong inducer contraindications
  • PMID 26367500Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid
  • ev_simvastatin_label_cyp3a4Simvastatin (Zocor) Prescribing Information — Contraindicated and dose-limited interactions
  • PMID 35152405CPIC Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms
critical Antibiotics, Antifungals, and Antivirals interaction_example

Darunavir + rifampin

Darunavir + Rifampin

Review question

Darunavir exposure may rise with Rifampin

Can you check whether Darunavir side effects or monitoring needs could increase?

Mechanism summary

Darunavir exposure may rise with Rifampin

Rifampin may increase Darunavir exposure, raising Darunavir toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

critical Acid Suppression, GI, Minerals, and Binding Interactions interaction_or_pgx_example

Clopidogrel + omeprazole with CYP2C19 PM

Clopidogrel + Omeprazole; CYP2C19:PM

Review question

Clopidogrel activation to Active thiol metabolite may be reduced with Omeprazole

Can you check whether Clopidogrel may work less well with my current list?

Mechanism summary

Clopidogrel activation to Active thiol metabolite may be reduced with Omeprazole

Increased stent thrombosis and MI risk. FDA warning Additional grouped signal: Clopidogrel exposure may fall with Omeprazole; CYP2C19 behaves as poor function. Related genotype, pathway, and metabolite signals are grouped below.

Evidence status

rct · 7 sources · mechanistic high · authority-linked

  • PMID 35034351Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
  • PMID 32770672CPIC Guideline for CYP2C19 and Proton Pump Inhibitor Dosing
  • PMID 25196410CYP2C19 phenotype effect on clopidogrel active thiol metabolite exposure and platelet inhibition
  • PMID 19106084Cytochrome P-450 polymorphisms and response to clopidogrel
  • PMID 24710841Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers
moderate Acid Suppression, GI, Minerals, and Binding Interactions interaction_example

Erlotinib + omeprazole

Erlotinib + Omeprazole

Review question

Erlotinib absorption may fall with Omeprazole

Can you check whether Erlotinib may not absorb as expected with my current list?

Mechanism summary

Erlotinib absorption may fall with Omeprazole

↓↓ Marked 46% reduction in erlotinib systemic bio-availability, risking premature oncology therapeutic failure. Additional grouped signal: CYP3A4 behaves as intermediate function.

Evidence status

observational · 5 sources · mechanistic moderate · primary-literature linked

  • PMID 31045210Effect of Proton Pump Inhibitors on the Pharmacokinetics of Erlotinib in Non-Small Cell Lung Cancer
moderate Acid Suppression, GI, Minerals, and Binding Interactions interaction_example

Erlotinib + famotidine

Erlotinib + Famotidine

Review question

Erlotinib absorption may fall with Famotidine

Can you check whether Erlotinib may not absorb as expected with my current list?

Mechanism summary

Erlotinib absorption may fall with Famotidine

Reduced EGFR TKI exposure; use label timing strategy or avoid chronic acid suppression when possible.

Evidence status

observational · 1 source · mechanistic moderate · primary-literature linked

  • PMID 31045210Effect of Proton Pump Inhibitors on the Pharmacokinetics of Erlotinib in Non-Small Cell Lung Cancer
moderate Acid Suppression, GI, Minerals, and Binding Interactions interaction_example

Levothyroxine + iron

Levothyroxine + Iron

Review question

Levothyroxine absorption may fall with Iron

Can you check whether Levothyroxine may not absorb as expected with my current list?

Mechanism summary

Levothyroxine absorption may fall with Iron

Reduced levothyroxine exposure; separate administration and monitor thyroid response after chronic iron use.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

moderate Acid Suppression, GI, Minerals, and Binding Interactions interaction_example

Levothyroxine + calcium

Levothyroxine + Calcium

Review question

Levothyroxine absorption may fall with Calcium

Can you check whether Levothyroxine may not absorb as expected with my current list?

Mechanism summary

Levothyroxine absorption may fall with Calcium

Reduced levothyroxine exposure and possible hypothyroid breakthrough; separate administration and monitor TSH after chronic changes.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

moderate Acid Suppression, GI, Minerals, and Binding Interactions interaction_example

Ciprofloxacin + iron

Ciprofloxacin + Iron

Review question

Ciprofloxacin absorption may fall with Iron

Can you check whether Ciprofloxacin may not absorb as expected with my current list?

Mechanism summary

Ciprofloxacin absorption may fall with Iron

Reduced antibiotic exposure; separate ciprofloxacin from iron-containing products.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

moderate Acid Suppression, GI, Minerals, and Binding Interactions interaction_example

Doxycycline + calcium

Doxycycline + Calcium

Review question

Doxycycline absorption may fall with Calcium

Can you check whether Doxycycline may not absorb as expected with my current list?

Mechanism summary

Doxycycline absorption may fall with Calcium

Reduced doxycycline exposure and possible treatment failure; separate dosing from calcium products.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

moderate Acid Suppression, GI, Minerals, and Binding Interactions interaction_example

Bictegravir + iron

Bictegravir + Iron

Review question

Iron absorption may fall with Bictegravir

Can you check whether Iron may not absorb as expected with my current list?

Mechanism summary

Iron absorption may fall with Bictegravir

Use label timing/food strategy; treatment failure risk matters when mineral use is chronic.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

severe Contraception, Hormones, and Reproductive Health interaction_example

Combined oral contraceptive + rifampin

Combined Oral Contraceptive + Rifampin

Review question

Rifampin exposure may rise with Combined Oral Contraceptive

Can you check whether Rifampin side effects or monitoring needs could increase?

Mechanism summary

Rifampin exposure may rise with Combined Oral Contraceptive

Combined Oral Contraceptive may increase Rifampin exposure, raising Rifampin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

  • ev_coc_labelCombined oral contraceptive prescribing information - enzyme induction and lamotrigine interaction
moderate Contraception, Hormones, and Reproductive Health interaction_example

Combined oral contraceptive + carbamazepine

Combined Oral Contraceptive + Carbamazepine

Review question

Carbamazepine exposure may rise with Combined Oral Contraceptive

Can you check whether Carbamazepine side effects or monitoring needs could increase?

Mechanism summary

Carbamazepine exposure may rise with Combined Oral Contraceptive

Combined Oral Contraceptive may increase Carbamazepine exposure, raising Carbamazepine toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 4 sources · mechanistic high · authority-linked

  • ev_coc_labelCombined oral contraceptive prescribing information - enzyme induction and lamotrigine interaction
moderate Contraception, Hormones, and Reproductive Health interaction_example

Combined oral contraceptive + lamotrigine

Combined Oral Contraceptive + Lamotrigine

Review question

Lamotrigine exposure may fall with Combined Oral Contraceptive

Can you check whether Lamotrigine may work less well with my current list?

Mechanism summary

Lamotrigine exposure may fall with Combined Oral Contraceptive

Combined Oral Contraceptive may reduce Lamotrigine exposure or effect. Related pathway and timing signals are grouped below.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

  • ev_coc_labelCombined oral contraceptive prescribing information - enzyme induction and lamotrigine interaction
severe Contraception, Hormones, and Reproductive Health interaction_example

Ethinyl estradiol + rifampin

Ethinyl Estradiol + Rifampin

Review question

Rifampin exposure may fall with Ethinyl Estradiol

Can you check whether Rifampin may work less well with my current list?

Mechanism summary

Rifampin exposure may fall with Ethinyl Estradiol

Ethinyl Estradiol may reduce Rifampin exposure or effect. Related pathway and timing signals are grouped below.

Evidence status

guideline · 1 source · mechanistic high · linked source

severe Contraception, Hormones, and Reproductive Health interaction_example

Ethinyl estradiol + lamotrigine

Ethinyl Estradiol + Lamotrigine

Review question

Lamotrigine exposure may fall with Ethinyl Estradiol

Can you check whether Lamotrigine may work less well with my current list?

Mechanism summary

Lamotrigine exposure may fall with Ethinyl Estradiol

Ethinyl Estradiol may reduce Lamotrigine exposure or effect. Related pathway and timing signals are grouped below.

Evidence status

clinical pk · 1 source · mechanistic high · primary-literature linked

  • PMID 16146436Ethinyl estradiol-containing contraceptives induce lamotrigine glucuronidation
severe Contraception, Hormones, and Reproductive Health interaction_example

Levonorgestrel + efavirenz

Levonorgestrel + Efavirenz

Review question

Levonorgestrel exposure may fall with Efavirenz

Can you check whether Levonorgestrel may work less well with my current list?

Mechanism summary

Levonorgestrel exposure may fall with Efavirenz

Efavirenz may reduce Levonorgestrel exposure or effect. Related pathway and timing signals are grouped below.

Evidence status

clinical pk · 1 source · mechanistic high · primary-literature linked

  • PMID 25393993Efavirenz interaction with levonorgestrel-containing contraception
moderate Contraception, Hormones, and Reproductive Health interaction_example

Sugammadex + ethinyl estradiol

Sugammadex + Ethinyl Estradiol

Review question

Sugammadex absorption may fall with Ethinyl Estradiol

Can you check whether Sugammadex may not absorb as expected with my current list?

Mechanism summary

Sugammadex absorption may fall with Ethinyl Estradiol

Use backup contraception for 7 days after sugammadex exposure.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

severe Contraception, Hormones, and Reproductive Health interaction_example

Pregnancy / trying to conceive + warfarin

Pregnancy / Trying to Conceive + Warfarin

Review question

Bleeding burden may rise

Can you check whether Warfarin + Pregnancy / Trying to Conceive needs closer bleeding or clotting monitoring?

Mechanism summary

Bleeding burden may rise

Bleeding burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

guideline · 2 sources · mechanistic high · authority-linked

  • ev_pregnancy_obstetric_workflowPregnancy and obstetric emergency medication workflow coverage: teratogenic exposure flags, hypertensive emergency, magnesium, uterotonics, hemorrhage, Rh prophylaxis, and vaccine timing
  • PMID 28198005CPIC Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update
severe QT Risk, Antiarrhythmics, and Rate Control interaction_or_pgx_example

Flecainide + fluoxetine with CYP2D6 PM

Flecainide + Fluoxetine; CYP2D6:PM

Review question

Flecainide exposure may rise with Fluoxetine

Can you check whether Flecainide side effects or monitoring needs could increase?

Mechanism summary

Flecainide exposure may rise with Fluoxetine

Fluoxetine may increase Flecainide exposure, raising Flecainide toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 8 sources · mechanistic high · authority-linked

  • PMID 9626731Flecainide prescribing information — CYP2D6 metabolism and interaction with CYP2D6 inhibitors
  • PMID 29325010Flecainide toxicity risks driven by CYP2D6 Poor Metabolizer status and Renal Insufficiency
  • ev_fluoxetine_cyp2d6_fdaProzac (fluoxetine) Prescribing Information — Drug Interactions
  • PMID 20184222Stereoselective pharmacokinetics of fluoxetine and norfluoxetine in CYP2D6 poor and extensive metabolizers
severe QT Risk, Antiarrhythmics, and Rate Control interaction_example

Amiodarone + warfarin

Amiodarone + Warfarin

Review question

Warfarin INR sensitivity may increase

Can you check whether Warfarin side effects or monitoring needs could increase?

Mechanism summary

Warfarin INR sensitivity may increase

Amiodarone may increase Warfarin exposure, raising Warfarin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

guideline · 7 sources · mechanistic high · authority-linked

  • PMID 3401099The incidence, magnitude, and time course of the amiodarone-warfarin interaction
  • PMID 28198005CPIC Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update
critical QT Risk, Antiarrhythmics, and Rate Control interaction_example

Dofetilide + hydrochlorothiazide

Dofetilide + Hydrochlorothiazide

Review question

Dofetilide exposure may rise with Hydrochlorothiazide

Can you check whether Dofetilide side effects or monitoring needs could increase?

Mechanism summary

Dofetilide exposure may rise with Hydrochlorothiazide

Hydrochlorothiazide may increase Dofetilide exposure, raising Dofetilide toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

critical QT Risk, Antiarrhythmics, and Rate Control interaction_example

Dofetilide + cimetidine

Dofetilide + Cimetidine

Review question

Dofetilide exposure may rise with Cimetidine

Can you check whether Dofetilide side effects or monitoring needs could increase?

Mechanism summary

Dofetilide exposure may rise with Cimetidine

Cimetidine may increase Dofetilide exposure, raising Dofetilide toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 4 sources · mechanistic high · authority-linked

moderate QT Risk, Antiarrhythmics, and Rate Control interaction_example

Sotalol + hydrochlorothiazide

Sotalol + Hydrochlorothiazide

Review question

Hydrochlorothiazide exposure may rise with Sotalol

Can you check whether Hydrochlorothiazide side effects or monitoring needs could increase?

Mechanism summary

Hydrochlorothiazide exposure may rise with Sotalol

Sotalol may increase Hydrochlorothiazide exposure, raising Hydrochlorothiazide toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 1 source · mechanistic high · authority-linked

moderate QT Risk, Antiarrhythmics, and Rate Control interaction_example

Ranolazine + diltiazem

Ranolazine + Diltiazem

Review question

Ranolazine exposure may rise with Diltiazem

Can you check whether Ranolazine side effects or monitoring needs could increase?

Mechanism summary

Ranolazine exposure may rise with Diltiazem

Diltiazem may increase Ranolazine exposure, raising Ranolazine toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 5 sources · mechanistic high · authority-linked

critical QT Risk, Antiarrhythmics, and Rate Control interaction_example

Ivabradine + clarithromycin

Ivabradine + Clarithromycin

Review question

Slow heart-rate risk may increase

Can you check whether this combination could slow my heart rate or pulse too much?

Mechanism summary

Slow heart-rate risk may increase

Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

fda label · 5 sources · mechanistic high · authority-linked

moderate QT Risk, Antiarrhythmics, and Rate Control interaction_example

Propafenone + metoprolol

Propafenone + Metoprolol

Review question

Low blood pressure risk may increase

Can you check whether my gene result could raise Metoprolol side effects, pulse, blood pressure, or monitoring needs?

Mechanism summary

Low blood pressure risk may increase

Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.

Evidence status

fda label · 5 sources · mechanistic high · authority-linked

moderate Oncology, Immunology, and Transplant interaction_example

Tacrolimus + fluconazole

Tacrolimus + Fluconazole

Review question

Tacrolimus exposure may rise with Fluconazole

Can you check whether this combination could raise Tacrolimus side effects or monitoring needs?

Mechanism summary

Tacrolimus exposure may rise with Fluconazole

Fluconazole may increase Tacrolimus exposure, raising Tacrolimus toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

guideline · 8 sources · mechanistic high · authority-linked

  • PMID 25801146Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
  • PMID 40604035Donor and recipient genetic variants in drug metabolizing enzymes and transporters affect early tacrolimus pharmacokinetics after liver transplantation
  • PMID 34916931Pharmacogenetics Based Dose Prediction Model for Initial Tacrolimus Dosing in Renal Transplant Recipients
  • PMID 25813372Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP3A5 Genotype and Tacrolimus Dosing
severe Oncology, Immunology, and Transplant interaction_example

Tacrolimus + clarithromycin

Tacrolimus + Clarithromycin

Review question

Tacrolimus exposure may rise with Clarithromycin

Can you check whether this combination could raise Tacrolimus side effects or monitoring needs?

Mechanism summary

Tacrolimus exposure may rise with Clarithromycin

Clarithromycin may increase Tacrolimus exposure, raising Tacrolimus toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

guideline · 9 sources · mechanistic high · authority-linked

  • ev_transplant_perioperative_workflowTransplant perioperative and immunosuppression medication workflow coverage: induction biologics, calcineurin/mTOR TDM, infection prophylaxis, CMV therapy, live vaccines, and nephrotoxicity
  • PMID 25813372Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP3A5 Genotype and Tacrolimus Dosing
  • PMID 25801146Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
  • PMID 40604035Donor and recipient genetic variants in drug metabolizing enzymes and transporters affect early tacrolimus pharmacokinetics after liver transplantation
  • PMID 34916931Pharmacogenetics Based Dose Prediction Model for Initial Tacrolimus Dosing in Renal Transplant Recipients
severe Oncology, Immunology, and Transplant interaction_example

Cyclosporine + posaconazole

Cyclosporine + Posaconazole

Review question

Cyclosporine exposure may rise with Posaconazole

Can you check whether Cyclosporine side effects or monitoring needs could increase?

Mechanism summary

Cyclosporine exposure may rise with Posaconazole

Posaconazole may increase Cyclosporine exposure, raising Cyclosporine toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

guideline · 5 sources · mechanistic high · linked source

  • ev_transplant_perioperative_workflowTransplant perioperative and immunosuppression medication workflow coverage: induction biologics, calcineurin/mTOR TDM, infection prophylaxis, CMV therapy, live vaccines, and nephrotoxicity
severe Oncology, Immunology, and Transplant interaction_or_pgx_example

Azathioprine + allopurinol with TPMT/NUDT15 PM

Azathioprine + Allopurinol; TPMT:PM, NUDT15:PM

Review question

6-Thioguanine nucleotides (6-TGN) may accumulate from Azathioprine

Can you check whether Azathioprine side effects or monitoring needs could increase?

Mechanism summary

6-Thioguanine nucleotides (6-TGN) may accumulate from Azathioprine

Allopurinol may increase Azathioprine exposure, raising Azathioprine toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 2 sources · mechanistic high · authority-linked

severe Oncology, Immunology, and Transplant interaction_or_pgx_example

Capecitabine with DPYD PM

Capecitabine; DPYD:PM

Review question

5-Fluorouracil may accumulate from Capecitabine

Can you check whether Capecitabine side effects or monitoring needs could increase?

Mechanism summary

5-Fluorouracil may accumulate from Capecitabine

toxic metabolite accumulation: parent neutral, toxic metabolite up. 5-FU from capecitabine accumulates -> life-threatening toxicity

Evidence status

guideline · 2 sources · mechanistic high · linked source

  • PMID 29152729CPIC Guideline for Fluoropyrimidines and DPYD Genotype
severe Oncology, Immunology, and Transplant interaction_or_pgx_example

Irinotecan with UGT1A1 PM

Irinotecan; UGT1A1:PM

Review question

SN-38 may accumulate from Irinotecan

Can you check whether Irinotecan side effects or monitoring needs could increase?

Mechanism summary

SN-38 may accumulate from Irinotecan

toxic metabolite accumulation: parent neutral, toxic metabolite up. SN-38 exposure higher; reduce starting dose and monitor CBC

Evidence status

guideline · 6 sources · mechanistic high · primary-literature linked

  • PMID 24786769CPIC Guideline for Irinotecan Therapy Based on UGT1A1 Genotype
  • PMID 17577039UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan
  • PMID 16636344Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in irinotecan/cisplatin
  • PMID 11489791Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
critical Oncology, Immunology, and Transplant interaction_example

Venetoclax + ritonavir

Venetoclax + Ritonavir

Review question

Venetoclax exposure may rise with Ritonavir

Can you check whether Venetoclax side effects or monitoring needs could increase?

Mechanism summary

Venetoclax exposure may rise with Ritonavir

Ritonavir may increase Venetoclax exposure, raising Venetoclax toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 5 sources · mechanistic high · authority-linked

severe Oncology, Immunology, and Transplant interaction_example

Erlotinib + rifampin

Erlotinib + Rifampin

Review question

Erlotinib exposure may rise with Rifampin

Can you check whether Erlotinib side effects or monitoring needs could increase?

Mechanism summary

Erlotinib exposure may rise with Rifampin

Rifampin may increase Erlotinib exposure, raising Erlotinib toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.

Evidence status

fda label · 3 sources · mechanistic high · authority-linked

  • PMID 16203810Erlotinib (Tarceva) prescribing information — CYP3A4/CYP1A2 metabolism and smoking interaction